Tirzepatide Receives Expanded Approval for MACE in Patients With T2D

The FDA approved tirzepatide (Mounjaro) for lowering the risk of major adverse cardiovascular events (MACE) among adults with type 2 diabetes (T2D), according to a release from Eli Lilly.¹

“Heart health deserves attention throughout the course of treatment, not just after a serious cardiovascular event,” David A. D'Alessio, MD, study co-author and director of the Division of Endocrinology and Metabolism at Duke University School of Medicine, said in a news release. “While a large portion of T2D care is focused on glucose control, mitigating cardiovascular risk is essential and can be overlooked.”

The regulatory green light for this expanded indication is grounded in the findings of the SURPASS-CVOT clinical trial. This landmark study marks the first head-to-head trial comparing 2 incretin medicines rather than comparing them against a placebo.¹

READ MORE: Patients With CVD Trust Pharmacists, Underuse Preventive Services

Enrolling over 13,000 participants across 30 countries for over 4 years, the trial demonstrated that tirzepatide was noninferior to dulaglutide (Trulicity), a glucagon-like peptide-1 (GLP-1) treatment with established cardiovascular benefits. Patients treated with tirzepatide experienced an 8% lower rate of cardiovascular death, heart attack, or stroke compared with dulaglutide, proving its efficacy in mitigating cardiorenal risk.

Trial Insights and Real-World Evidence

Although randomized clinical trials remain the gold standard, real-world observational evidence provides validation. In a comparative study featured in Inside Precision Medicine, researchers analyzed health data from over 52,000 US adults over 40 years old with T2D and established atherosclerotic cardiovascular disease.²

The investigation benchmarked tirzepatide against sitagliptin, a dipeptidyl peptidase 4 inhibitor chosen as a neutral proxy due to its lack of documented cardiovascular effects. Over a 1-year monitoring period, the cohort receiving tirzepatide demonstrated a striking 32% reduction in the risk of MACE compared with sitagliptin.

A related editorial in BMJ highlighted that despite this signal being compelling, proving incremental benefits over other optimized background therapies like sodium-glucose transport protein 2 inhibitors requires randomized background comparison.²

This real-world cardiorenal signal is further contextualized by a sweeping meta-analysis of randomized controlled trials. In a study published in the American Journal of Preventive Cardiology, researchers analyzed data from 13 trials comprising over 83,000 patients.³

The meta-analysis revealed that GLP-1 receptor agonists achieved a 14% overall reduction in MACE and a 13% reduction in all-cause mortality compared with placebo. The benefits persisted regardless of the patient's biological sex, baseline body mass index, or history of cardiovascular disease. The researchers also noted a significant 24% reduction in broad composite renal outcomes, showcasing incretin-based therapies as powerful, multiorgan protective agents.

Elevating the Pharmacist's Role

The expansion of tirzepatide's clinical indications places pharmacists at the forefront of modern care. The clinical and economic impact of pharmacist integration is thoroughly examined in the Pan American Health Organization’s policy paper, “HEARTS Pharmacy: A framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary care.”⁴

The HEARTS Pharmacy framework emphasizes that pharmacist-led interventions, including medication titration and team-based care, are highly cost-effective and drastically improve patients’ clinical outcomes, such as low-density lipoprotein cholesterol and blood pressure levels. With specialized training in drug interactions, adverse effects, and adherence barriers, pharmacists are crucial in safely managing complex patients with overlapping comorbidities like T2D and cardiovascular disease.

Overcoming Barriers Cardiovascular Interventions

Despite the clear clinical value that pharmacists bring, operational challenges persist. A nationwide cross-sectional study in Malaysia investigated the role of community pharmacists in cardiovascular health promotion and dyslipidemia services.⁵

The survey revealed that despite pharmacists excelling at patient counseling, major operational barriers exist. Specifically, 71.2% of surveyed community pharmacists cited a lack of access to patient medical records as their primary hurdle, and 70.8% reported a severe shortage of structured cardiovascular educational materials. Workload issues and a lack of interdisciplinary communication with prescribing physicians also hinder collaborative therapy adjustments.

To address these barriers and leverage the pharmacist’s clinical potential, the Malaysian study authors call for structural reforms, including the implementation of centralized, computerized health records to safely share data between community pharmacies and primary clinics.⁵

The FDA’s expanded approval of tirzepatide represents a major advance in diabetes and cardiovascular care. By actively participating in team-based care models, optimizing patient adherence, and conducting evidence-based counseling, pharmacists can translate these landmark clinical trial findings into real-world health outcomes, significantly reducing the global burden of cardiovascular disease.^1,4

“This approval gives patients a medicine that reduces the risk of cardiovascular events and supports metabolic health at the same time,” concluded D'Alessio, according to Eli Lilly’s release.¹

READ MORE: Diabetes Resource Center

REFERENCES

1. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. News Release. Eli Lilly. August 28, 2026. Accessed August 31, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular

2. MACE risk may be reduced with GLP-1 drug in high-risk patients. Inside Precision Medicine. August 6, 2026. Accessed August 31, 2026. https://www.insideprecisionmedicine.com/topics/precision-medicine/mace-risk-may-be-reduced-with-glp-1-drug-in-high-risk-patients/

3. Rivera FB, Cruz LLA, Magalong JV, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024 May 7;18:100679. doi: 10.1016/j.ajpc.2024

4. Ridley E, DiPette DJ, Gysel S, et al. HEARTS Pharmacy: a framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary care. Rev Panam Salud Publica. 2025 Apr 18;49:e35. doi: 10.26633/RPSP.2025.35

5. Ismail FF, Md Redzuan A, Chong WW, et al. Role of community pharmacists in cardiovascular diseases-related health promotion and dyslipidemia management in Malaysia: a nationwide cross-sectional study. PLoS One. 2023 Sep 28;18(9):e0290883. doi: 10.1371/journal.pone.0290883